论文部分内容阅读
糖尿病血管并发症严重影响患者的生存质量,甚至威胁生命。近年研究发现,内皮祖细胞(EPCs)的变化可能是糖尿病及其血管并发症发生的重要原因。本文对EPCs减少和功能异常在各种糖尿病血管并发症中的作用及可能的干预治疗的前景作一综述。一、EPCs概述EPCs由Asahara于1997年首次在血液中发现。它们是一群能分化成成熟内皮而参与血管新生的非成熟细胞。EPCs既有造血细胞的标志(如CD34和(CD133),也有内皮系细胞的标志(如KDR、CD31和vWf)。EPCs来源于骨髓,在
Diabetic vascular complications seriously affect the quality of life of patients, and even life-threatening. Recent studies have found that endothelial progenitor cells (EPCs) changes may be an important cause of diabetes and its vascular complications. This article reviews the role of EPCs reduction and dysfunction in various diabetic vascular complications and possible interventions. First, the EPCs Overview EPCs by Asahara first discovered in the blood in 1997. They are a group of immature cells that can differentiate into mature endothelium and participate in angiogenesis. EPCs have both hematopoietic markers (such as CD34 and CD133) and markers of endothelial cells (such as KDR, CD31 and vWf)